Clinical trial of mebendazole, a broad-spectrum anthelminthic.
Eighty-five children aged 5-14 years who were infested with worms were treated with mebendazole 100 mg twice daily for three days. The percentage cure rates were ascaris 100%, trichuris 94%, hookworm 82%, and hymenolepis 39%. The drug was well tolerated and with its broad activity should be very useful in treating those with multiple infestations.
D000293:Adolescent; D000871:Anthelmintics / Q000627:therapeutic use*; D001196:Ascariasis / Q000188:drug therapy; D001562:Benzimidazoles / Q000627:therapeutic use*; D002648:Child; D005260:Female; D005873:Giardiasis / Q000188:drug therapy; D006373:Helminthiasis / Q000188:drug therapy*; D006725:Hookworm Infections / Q000188:drug therapy; D006801:Humans; D006925:Hymenolepiasis / Q000188:drug therapy; D008297:Male; D008463:Mebendazole / Q000627:therapeutic use*; D011247:Pregnancy; D013622:Taeniasis / Q000188:drug therapy; D014257:Trichuriasis / Q000188:drug therapy
D000871:Anthelmintics; D001562:Benzimidazoles; D008463:Mebendazole